Alligator Bioscience
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company specializes in creating antibody-based pharmaceuticals designed to activate the patient's immune system for cancer treatment. Its proprietary technology platform and drug discovery engine support a pipeline of immunotherapies, with a significant focus on the CD40 pathway. A key product in its pipeline is mitazalimab, a CD40 agonist being developed for hard-to-treat cancers, including pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-03 15:00 |
Board/Management Information
Valberedning utsedd inför årsstämma 2026 i Alligator Bioscience AB
|
Swedish | 61.0 KB | ||
| 2025-11-03 15:00 |
Board/Management Information
Nomination Committee appointed in respect of AGM 2026 in Alligator Bioscience AB
|
English | 61.7 KB | ||
| 2025-10-23 08:00 |
Quarterly Report
|
Swedish | 1.2 MB | ||
| 2025-10-23 08:00 |
Quarterly Report
|
English | 1.2 MB | ||
| 2025-10-22 23:55 |
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Alligator Bioscience AB
|
Swedish | 93.3 KB | ||
| 2025-10-22 23:55 |
Pre-Annual General Meeting Information
Notice of extraordinary general meeting in Alligator Bioscience AB
|
English | 98.5 KB | ||
| 2025-10-22 23:05 |
Share Issue/Capital Change
Alligator Bioscience carries out a rights issue of units of approximately SEK 1…
|
English | 114.4 KB | ||
| 2025-10-22 23:05 |
Share Issue/Capital Change
Alligator Bioscience genomför en företrädesemission av units om cirka 120 MSEK …
|
Swedish | 113.8 KB | ||
| 2025-10-17 09:50 |
Major Shareholding Notification
|
Swedish | 10.5 KB | ||
| 2025-10-14 11:07 |
Major Shareholding Notification
|
Swedish | 10.9 KB | ||
| 2025-10-13 11:43 |
Major Shareholding Notification
|
Swedish | 9.6 KB | ||
| 2025-10-09 11:42 |
Major Shareholding Notification
|
Swedish | 10.9 KB | ||
| 2025-10-06 10:45 |
Major Shareholding Notification
|
Swedish | 10.9 KB | ||
| 2025-10-03 10:45 |
Major Shareholding Notification
|
Swedish | 10.9 KB | ||
| 2025-10-01 09:40 |
Major Shareholding Notification
|
Swedish | 10.1 KB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
